X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
Erasca intends to use the net proceeds to fund the research and development of its product candidates and other development programs, including ERAS-254 (naporafenib) administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 27, 2024
Details:
The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2024
Details:
LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
Tafinlar is a combination of dabrafenib mesylate and trametinib that targets two different kinases in the RAS/RAF/MEK/ERK pathway. This combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines.
Lead Product(s): Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: Tafinlar
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600 mutant targets. C4T is advancing CFT1946 to the clinic to study treatment for BRAF V600 mutant solid tumors including NSCLC, colorectal cancer, and melanoma.
Lead Product(s): CFT1946,Trametinib
Therapeutic Area: Oncology Product Name: CFT1946
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
DCC-3116 is orally administered, potent, and highly selective switch-control inhibitor designed to inhibit cancer autophagy, key tumor survival mechanism in cancer cells, by inhibiting ULK1/2 kinases, which have been shown to be enzymes responsible for initiating autophagy.
Lead Product(s): DCC-3116,Trametinib
Therapeutic Area: Oncology Product Name: DCC-3116
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
SNR1611 (trametinib) was the first drug candidate identified at Genuv with the ATRIVIEW® platform. It showed the most potent neurogenerative and neuroprotective effects in a library of FDA-approved drug compounds.
Lead Product(s): Trametinib
Therapeutic Area: Neurology Product Name: SNR1611
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
FDA approval was based on clinical efficacy and safety demonstrated in three clinical trials. In Phase II ROAR basket study and NCI-MATCH Subprotocol H study, Tafinlar (dabrafenib mesylate) + Mekinist resulted in overall response rates of up to 80% in patients with BRAF V600E.
Lead Product(s): Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: Tafinlar
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
Treatment with targeted therapies Tafinlar (dabrafenib)+ Mekinist resulted in 47% ORR versus chemotherapy and reduced risk of progression or death by 69%, showing significant efficacy improvement in patients with BRAF V600 LGG requiring first systemic treatment.
Lead Product(s): Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: Tafinlar
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
The Phase 1b portion of the study will examine the safety, tolerability, pharmacokinetics, and any early signals of efficacy of repotrectinib in combination with trametinib in patients with KRAS G12D mutated advanced solid tumors.
Lead Product(s): Repotrectinib,Trametinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Tafinlar (dabrafenib) and Mekinist (trametinib) are approved in combination to treat people with a type of skin cancer called melanoma, non-small cell lung cancer and anaplastic thyroid cancer.
Lead Product(s): Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: Tafinlar
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2020
Details:
PDR001 (spartalizumab) is an investigational monoclonal antibody directed against the human programmed death-1 (PD-1) receptor. Its development program continues, and investigating the immunotherapy across a range of tumor types.
Lead Product(s): Spartalizumab,Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: PDR001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2020
Details:
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma.
Lead Product(s): Spartalizumab,Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: PDR001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2020
Details:
In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
Lead Product(s): Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: MEDI4736
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
Novarti's cancer-fighting duo Tafinlar and Mekinist alongside its experimental PD-1-blocking spartalizumab banished tumors in 44% of patients with advanced melanoma, early data from a phase 3 study show.
Lead Product(s): Spartalizumab,Dabrafenib Mesylate,Trametinib
Therapeutic Area: Oncology Product Name: PDR001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
